Intense control activities, especially the continuous use of effective antimalarial drugs, apply significant selective pressure on the malaria parasite population. As transmission declines, most infected individuals carry single clones promoting a higher rate of inbreeding37 that favors the spread of drug resistance phenotypes when they arise.38,39 The independent emergence or spread of artemisinin resistance in Zambia due to drug selection pressure could significantly increase the malaria burden leading to malaria resurgence and increased morbidity and mortality.40 Close monitoring of the efficacy of available antimalarial drugs and improved surveillance for resistance mutations will be key to inform control strategies such that rapid action can be taken to mitigate the impact and slow or prevent the spread of drug resistant parasites.22,23
This nationally representative spatial analysis of antimalarial drug resistance mutations supports several conclusions that together strongly suggest that individual genes are under markedly different selection pressures. Firstly, there was a noticeable lack of mutations in Pfcrt codons 72–76 and a low number of polymorphisms (only seven unique NS mutations) across the gene. Zambia withdrew CQ treatment and therefore drug selective pressure on the Pfcrt gene in 2003 allowing reversion to the wild-type. While other studies have previously identified this reversion,35,41 the selection patterns in Zambia lacked a commonly selected region on chromosome 7 (Pfcrt), contrasting with parasite populations from other regions. Similarly, we did not observe selection signatures in Pfaat1, the second important transporter gene for chloroquine resistance.42 This is consistent with other African countries where CQ withdrawal resulted in declines in CQ resistance alleles and reductions in CQ median IC50 values.43,44 While this finding is encouraging in terms of the potential to reintroduce CQ as part of the chemotherapeutic arsenal in Zambia, preferably as a combination therapy, however additional phenotype-genotype association studies would be needed to confirm the susceptibility of this wild-type strain to CQ.
In contrast to CQ, SP resistance markers were highly prevalent throughout Zambia, suggesting strong selective pressure is maintained through national IPTp implementation and high private sector SP utilization without prescription for self-medication of suspected malaria.45 Pyrimethamine associated resistance in Pfdhfr was very high, with 95% of samples having triple mutants (IRN) and codon S108N (99.6%) approaching fixation with negligible spatial variation. A similar picture was observed for sulfadoxine associated Pfdhps mutations, with 84% double mutants (codons A437G and K540E). Overall, 82.9% of samples were Pfdhfr and Pfdhps quintuple mutants Pfdhfr-dhps (IRNGE) correlating with full genotypic SP resistance and expected treatment failure. Furthermore, with a concentration in Luapula and Northern Provinces, 5.3% (15/282) of samples also carried the Pfdhps A581G mutation in addition to the Pfdhfr-dhps IRNGE background. This genotype confers extreme SP resistance and is of concern for SP efficacy in Zambia. While some variation between this study and historical data29,46 may be explained by study differences (subject selection, sites, implementation period) and data type (PCR genotyping vs. WGS), overall a marked increase in SP genotypic resistance has occurred. Our findings are consistent with our previous evidence of positive selection for SP markers,31 as well as with other African countries where Pfdhfr–Pfdhps quintuple mutant prevalence is high, while the sextuple mutant remains rare,45,47 albeit with high spatial heterogeneity.4,48 While overall SP resistance is clearly high in Zambia, two mutations (Pfdhfr I164L49 and Pfdhps A613S/T47,50) that confer even higher SP resistance were not identified in Zambia.
The high prevalence of SP resistance (> 90%) are in children younger than five years) indicates a strong selective pressure has been applied to these genes, even though SP is primarily only used for IPTp. The WHO recommends that countries withdraw SP for IPTp use when the prevalence of Pfdhps K540E is > 95% and Pfdhps A581G is > 10%.11 At 87.6% and 5% respectively, Zambia as a country remains below these thresholds, although some districts e.g., Nchelenge and Mansa in Luapula Province, did exceed them. Based on these findings, SP should continue to be used for IPTp. In contrast, the WHO threshold for SP-based IPTi withdrawal is when K540E is > 50% and thus, SP would not be recommended to be used for IPTi in Zambia at this time.
Until novel therapies are developed, maintaining the efficacy of ART based treatments is fundamental to global control and elimination efforts. In Zambia, AL has been used as a first line combination antimalarial treatment for uncomplicated P. falciparum malaria since 2002.51 Considering the historical use and importance of ART to malaria control in Zambia, increased polymorphisms in the kelch13 gene and the identification three WHO-validated mutations associated with partial artemisinin resistance suggest an early signal of partial artemisinin resistance in Zambia. Close monitoring of local emerging or spreading kelch13 mutations (R561H, A675V and C469Y)52–54 that were recently reported from East Africa and confer partial artemisinin resistance is warranted. While not unexpected, it was also encouraging to note that no mutations (Pfcrt I356T, Pffd D193Y, Pfmdr2 T484I, Pfap2mu S160N and Pfubp1 E1528D) associated with ART resistance in Southeast Asia55 were identified. Nevertheless, considering the variation between Asian and African parasite populations,56 it is possible that other Africa-specific mutations may augment ART resistance. Similarly, we must continue to track all mutations in any key genes, irrespective of their genotypic resistance status. For example, 26 Pfkelch13 mutations were identified, including one (A578S) that has been commonly reported in Africa,2,29 the implications of which remains unclear. Unfortunately, while ART appears to be efficacious, the main partner drug lumefantrine does not fare as well, with all but two specimens containing one or more key mutations in Pfmdr1. In fact, more than 50% of all specimens carried mdr1 (NFD) haplotype. This confirms results provided by other studies performed in the Southern and Western Provinces of Zambia2,29,57 but, as with SP, the trend is that genotypic resistance is increasing. While this may not correlate with ACT clinical treatment failure with AL, it does potentially remove the partner drug from the combination therapy leaving ART exposed as monotherapy. Such an environment would be primed to enable rapid selection and spread of ART resistance irrespective of resistance evolving independently or through an introduction event into Zambia.
In summary, this study support two worrying and two encouraging conclusions with respect to antimalarial drug resistance. Firstly, Zambia has very high, and for some loci almost fixed, resistance to SP. While still under WHO recommended limits, this warrants further SP efficacy studies in pregnancy to assess the drugs’ ability to reduce deleterious maternal and birth outcomes, especially in Luapula and Northern Provinces where WHO frequency thresholds were crossed. Secondly, there are also very high levels of genotypic resistance to lumefantrine, the main ART partner ACT drug used in Zambia. While therapeutic efficacy studies have not identified significant treatment failure several years after these samples were collected, it may be prudent to switch to an alternative ACT in the near future, or at least prepare for a switch should treatment failures occur. Finally, there is some encouraging data, namely that CQ sensitivity has been restored and there is no evidence of ART resistance in Zambia. Together these findings along with the recent evidence of strong positive selection signatures genes involved in sulfadoxine-pyrimethamine and artemisinin combination therapies drug resistance31 highlight the need of sustained surveillance of antimalarial drug resistance across the country. Furthermore, this work underlines the utility of high-quality genomic surveillance, which if performed and acted upon, gives every chance of effective malaria treatment continuing for the foreseeable future despite the constant threat of drug resistance. Without surveillance, resistance will only be detected following treatment failure, at which point options to respond will be limited.